Echo-lucency of computerized ultrasound images of carotid atherosclerotic plaques are associated with increased levels of triglyceride- rich lipoproteins as well as increased plaque lipid content

Circulation

Volumn 97, Issue 1, 1998, Pages 34-40

  Grønholdt, Marie Louise M ^a   Nordestgaard, Børge G ^b   Wiebe, Britt M ^b   Wilhjelm, Jens E ^b   Sillesen, Henrik ^b  

^a Rigshospitalet   (Denmark)

^b NONE

Author keywords

Arteriosclerosis; Carotid arteries; Lipoproteins; Pathology; Ultrasonics

Indexed keywords

CHYLOMICRON; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; BODY MASS; BRAIN SCINTISCANNING; CAROTID ARTERY OBSTRUCTION; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; IMAGE ANALYSIS; LIPID COMPOSITION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0031983878     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.1.34     Document Type: Article

References (41)

1. Pyörälä K, Backer GD, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J. 1994;15:1300-1331.
2. Carleton RA, Chairman P, Dwyer J, Finberg L, Flora J, Goodman DWS, Grundy SM, Havas S, Hunter GT, Kritchevsky D, Lauer RM, Luepker RV, Ramirez AG, Horn LV, Stason WB, Stokes J 3rd. Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction: a statement from the National Cholesterol Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health. Circulation. 1991;83:2154-2232.
3. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
4. Brown G, Albers JJ, Fisher LD, Schaeffer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
5. Scandianvian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
6. Shephard J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
7. Sacks FM, Pfeffer MA, Lemuel AM, Roleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JMO, Wun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
8. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb. 1991;11:2-14.
9. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 1996;347:849-853.
10. Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, Nikkilä EA. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260:641-651.
11. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischemic Heart Disease Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223:405-418.
12. Gronholdt MLM, Nordestgaard BG, Nielsen TG, Sillesen H. Echolucent carotid artery plaques are associated with elevated levels of fasting and postprandial triglyceride-rich lipoproteins. Stroke. 1996;27:2166-2172.
13. European Carotid Plaque Study Group. Carotid artery plaque composition: relationship to clinical presentation and ultrasound B-mode imaging. Eur J Vasc Endovasc Surg. 1995;10:23-30.
14. Johnson JM, Kennelly MM, Decesare D, Morgan S, Sparrow A. Natural history of asymptomatic carotid plaque. Arch Surg. 1985;120:1010-1012.
15. Sterpetti AV, Schultz RD, Feldhaus RJ, Davenport KL, Richardson M, Farina C, Hunter WJ. Ultrasonographic features of carotid plaque and the risk of subsequent neurologic deficits. Surgery. 1988;104:652-660.
16. Bock RW, Gray-Weale AC, Mock PA, Robinson DA, Irwig L, Lusby RJ. The natural history of asymptomatic carotid artery disease. J Vasc Surg. 1993;17:160-169.
17. Iannuzzi A, Wilcosky T, Mercuri M, Rubba P, Bryan FA, Bond MG. Ultrasonic correlates of carotid atherosclerosis in transient ischemic attack and stroke. Stroke. 1995;26:614-619.
18. El-Barghouty NM, Geroulakos G, Nicolaides A, Androulakis A, Bahal V. Computer-assisted carotid plaque characterisation. Eur J Vasc Endovasc Surg. 1995;9:389-393.
19. El-Barghouty NM, Nicobidcs A, Bahal V, Geroulakos G, Androulakis A. The identification of the high risk carotid plaque. Eur J Vasc Ensovasc Surg. 1996;11:470-478.
20. El-Bargnoury NM, Levine T, Ladva S, Flanagan A, Nicolaides A. Histological verification of computerised carotid plaque characterisation. Eur J Vasc Endovasc Surg. 1996;11:414-416.
21. Brown SA, Chambless LE, Sharrett AR, Gotto AM Jr, Patsch W. Postprandial lipemia: reliability in an epidemiologic field study, Am J of Epidemiol. 1992;136:538-545.
22. Statistica for Windows. Tulsa, Okla: Stat Soft, Inc; 1994:1-3911.
23. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307-310.
24. Tatami R, Mabuchi H, Ueda K, Ueda R, Haba T, Kametani T, Ito S, Koizumi J, Ohta M, Miyamoto S, Nakayama A, Kanaya H, Oiwake H, Genda A, Takeda R. Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease. Circulation. 1981;64:1174-1184.
25. Reardon MF, Nestel PJ, Craig IH, Harper RW. Lipoprotein predictors of the severity of coronary artery disease in men and women. Circulation. 1985;71:881-888.
26. Steiner G, Schwartz L, Shumak S, Poapst M. The association of increased levels of intermediate-density lipoproteins with smoking and with coronary arten disease. Circulation 1987;75:124-130.
27. Krauss RM, Lindgren FT, Williams PT, Kelsey SF, Brensike J, Vranizan K, Detre KM, Levy RI. Intermediate-density lipoproteim and progression of coronary artery disease in hypercholesterolaemic men. Lancet. 1987;11:62-66.
28. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation. 1993;88:2762-2770.
29. Simons LA, Dwyer T, Simons J, Bernstein L, Mock P, Poonia NS, Balasubramaniam S, Baron D, Branson J, Morgan J, Roy P. Chylomicrons and chylomicron remnants in coronary artery disease: a case-control study. Atherosclerosis. 1987;65:181-189.
30. Simpson HS, Williamson CM, Olivacrona T, Pringle S, Maclean J, Lorimer AR, Bonnefous F, Bogaievsky Y, Packard CJ, Shephard J. Postprandial lipemia, fenofibrate and coronary artery disease. Arterisclerosis. 1990;85:193-202.
31. Groot PHE, van Stiphout WAHJ, Krauss XH, Jausen H, van Tol A, van Ramshorst E, Chin-On S, Hofman A, Cresswell SR, Havekes L. Postpranadial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Anterioscler Thromb. 1991;11:653-662.
32. Ryu JE, Howard G, Craven TE, Bond MG, Hagaman AP, Crouse JR III. Postprandial triglyceridemia and carotid atherosclerosis in middle-aged subjects. Stroke. 1992;23:823-828.
33. Patsch JR, Miesenböck G, Hopferwieser T, Mühlberger V, Knapp E, Dunn JK, Gotto AM Jr, Patsch W. Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscler Thromb. 1992;12:1336-1345.
34. Uiterwaal CSPM, Grobbee DE, Witteman JCM, van Stiphout WA, Krauss XH, Havekes LM, de Bruijn AM, van Tol A, Hofman A. Postprandial triglyceride response in young adult men and familial risk for coronary atherosclerosis. Ann Intern Med. 1994;121:576-583.
35. Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis. 1994;106:83-97.
36. Nordestgaard BG, Nielsen LB. Atherosclerosis and arterial influx of lipoproteins. Curr Opin Lipidol 1994;5:252-257.
37. Nordestgaard BG, Wooton R, Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipedemic rabbits in vivo: molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb Vasc Biol. 1995;15:534-542.
38. Rapp JH, Lespine A, Hamilton RL, Colyvas N, Chaumeton AH, Tweedie-Hardman J, Kotite L, Kunitake ST, Havel RJ, Kaue JP. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb. 1994;14:1767-1774.
39. Bradley WA, Gianturco SH. Triglyceride-rich lipoproteins and atherosclerosis: pathophysiological considerations. J Intern Med. 1994;236(suppl. 736):33-39.
40. Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W Jr, Rosenfeld ME, Shaeffer A, Schwartz CJ, Wagner WD, Wissler RW. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Atherosclerosis, American Heart Association. Arterioscler Thromb. 1994;14:840-856.
41. Gordon DJ, Probstfield JL, Garnison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR JR, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8-15